NASDAQ:GEVA - Synageva Biopharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Synageva BioPharma Corp. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for the treatment of rare diseases. The Company has a pipeline of protein therapeutic programs for rare diseases. Its lead product is Kanuma (sebelipase alfa) being developed for the treatment of lysosomal acid lipase deficiency (LAL Deficiency). The Company's other product candidates under development include SBC-103, a first-mover enzyme replacement therapy program for mucopolysaccharidosis IIIB (MPS IIIB, also known as Sanfilippo B syndrome) and SBC-105, which is a first-mover enzyme therapy in preclinical development for rare disorders of calcification, including the indication generalized calcification in infants (GACI). The Company also has additional first-mover and potentially bio-superior protein therapeutic pipeline programs for other rare diseases at different stages of preclinical development.

Receive GEVA News and Ratings via Email

Sign-up to receive the latest news and ratings for GEVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:GEVA
CUSIP87159A10
Phone+1-781-3579900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Synageva Biopharma (NASDAQ:GEVA) Frequently Asked Questions

What is Synageva Biopharma's stock symbol?

Synageva Biopharma trades on the NASDAQ under the ticker symbol "GEVA."

How were Synageva Biopharma's earnings last quarter?

Synageva Biopharma Corp (NASDAQ:GEVA) posted its quarterly earnings data on Thursday, February, 26th. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, missing the consensus estimate of ($1.71) by $0.02. The biopharmaceutical company earned $1.24 million during the quarter, compared to the consensus estimate of $1.25 million. View Synageva Biopharma's Earnings History.

Has Synageva Biopharma been receiving favorable news coverage?

News stories about GEVA stock have been trending somewhat positive this week, InfoTrie reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Synageva Biopharma earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 8.0 out of 10, meaning that recent media coverage is very likely to have an impact on the company's share price in the immediate future.

How do I buy shares of Synageva Biopharma?

Shares of GEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Synageva Biopharma's official website?

The official website for Synageva Biopharma is http://www.synageva.com.

How can I contact Synageva Biopharma?

Synageva Biopharma's mailing address is 33 Hayden Ave, LEXINGTON, MA 02421-7972, United States. The biopharmaceutical company can be reached via phone at +1-781-3579900.


MarketBeat Community Rating for Synageva Biopharma (NASDAQ GEVA)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  193 (Vote Outperform)
Underperform Votes:  135 (Vote Underperform)
Total Votes:  328
MarketBeat's community ratings are surveys of what our community members think about Synageva Biopharma and other stocks. Vote "Outperform" if you believe GEVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GEVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/19/2019 by MarketBeat.com Staff

Featured Article: What is a Derivative?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel